121 related articles for article (PubMed ID: 38176950)
21. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
22. Peiminine Reduces ARTS-Mediated Degradation of XIAP by Modulating the PINK1/Parkin Pathway to Ameliorate 6-Hydroxydopamine Toxicity and α-Synuclein Accumulation in Parkinson's Disease Models In Vivo and In Vitro.
Hsu YL; Hung HS; Tsai CW; Liu SP; Chiang YT; Kuo YH; Shyu WC; Lin SZ; Fu RH
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638579
[TBL] [Abstract][Full Text] [Related]
23. Maackiain Ameliorates 6-Hydroxydopamine and
Tsai RT; Tsai CW; Liu SP; Gao JX; Kuo YH; Chao PM; Hung HS; Shyu WC; Lin SZ; Fu RH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585871
[TBL] [Abstract][Full Text] [Related]
24. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
[TBL] [Abstract][Full Text] [Related]
25. Neurodegeneration and contralateral α-synuclein induction after intracerebral α-synuclein injections in the anterior olfactory nucleus of a Parkinson's disease A53T mouse model.
Flores-Cuadrado A; Saiz-Sanchez D; Mohedano-Moriano A; Martinez-Marcos A; Ubeda-Bañon I
Acta Neuropathol Commun; 2019 Apr; 7(1):56. PubMed ID: 30987677
[TBL] [Abstract][Full Text] [Related]
26. LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells.
Chen Y; Lian YJ; Ma YQ; Wu CJ; Zheng YK; Xie NC
Neurotoxicology; 2018 Sep; 68():212-221. PubMed ID: 29217406
[TBL] [Abstract][Full Text] [Related]
27. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells.
Smith WW; Margolis RL; Li X; Troncoso JC; Lee MK; Dawson VL; Dawson TM; Iwatsubo T; Ross CA
J Neurosci; 2005 Jun; 25(23):5544-52. PubMed ID: 15944382
[TBL] [Abstract][Full Text] [Related]
28. Genetic deletion of nitric oxide synthase 2 ameliorates Parkinson's disease pathology and neuroinflammation in a transgenic mouse model of synucleinopathy.
Kim J; Han JY; Lee Y; Kim K; Choi YP; Chae S; Hoe HS
Mol Brain; 2023 Jan; 16(1):7. PubMed ID: 36647152
[TBL] [Abstract][Full Text] [Related]
29. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice.
Unger EL; Eve DJ; Perez XA; Reichenbach DK; Xu Y; Lee MK; Andrews AM
Neurobiol Dis; 2006 Feb; 21(2):431-43. PubMed ID: 16230020
[TBL] [Abstract][Full Text] [Related]
30. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
[TBL] [Abstract][Full Text] [Related]
31. Usp14 deficiency removes α-synuclein by regulating S100A8/A9 in Parkinson's disease.
Ding L; Lu L; Zheng S; Zhang Z; Huang X; Ma R; Zhang M; Xu Z; Chen M; Guo Z; Zhu S; Gong J; Mao H; Zhang W; Xu P
Cell Mol Life Sci; 2024 May; 81(1):232. PubMed ID: 38780644
[TBL] [Abstract][Full Text] [Related]
32. Nigrostriatal dynein changes in A53T alpha-synuclein transgenic mice.
Liu Y; Yuan YH; Sun JD; Li J; Li ZP; Chen NH
F1000Res; 2014; 3():68. PubMed ID: 25210616
[TBL] [Abstract][Full Text] [Related]
33. Tenuigenin attenuates α-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3.
Zhou JX; Zhang HB; Huang Y; He Y; Zheng Y; Anderson JP; Gai WP; Liang ZG; Wang Y; Ren XM; Wang Q; Gong XL; Yang J; Wang X; Halliday G; Wang XM
CNS Neurosci Ther; 2013 Sep; 19(9):688-94. PubMed ID: 23710708
[TBL] [Abstract][Full Text] [Related]
34. A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration.
Chen L; Xie Z; Turkson S; Zhuang X
J Neurosci; 2015 Jan; 35(3):890-905. PubMed ID: 25609609
[TBL] [Abstract][Full Text] [Related]
35. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
36. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
[TBL] [Abstract][Full Text] [Related]
37. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease.
Melo TQ; van Zomeren KC; Ferrari MF; Boddeke HW; Copray JC
Exp Brain Res; 2017 Mar; 235(3):731-742. PubMed ID: 27866262
[TBL] [Abstract][Full Text] [Related]
38. Effects of Ginkgo Biloba Extract on A53T α-Synuclein Transgenic Mouse Models of Parkinson's Disease.
Kuang S; Yang L; Rao Z; Zhong Z; Li J; Zhong H; Dai L; Tang X
Can J Neurol Sci; 2018 Mar; 45(2):182-187. PubMed ID: 29506601
[TBL] [Abstract][Full Text] [Related]
39. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.
George S; Mok SS; Nurjono M; Ayton S; Finkelstein DI; Masters CL; Li QX; Culvenor JG
J Mol Neurosci; 2010 Oct; 42(2):243-54. PubMed ID: 20464527
[TBL] [Abstract][Full Text] [Related]
40. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
